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The inception of tumor microenvironment (TME), a complex and dynamic system constituted by different types 
of cells engaged by tumor and extracellular matrix surrounding cancer cells, is a way for them to elude the 
immune surveillance. Dendritic cells (DCs), as a sentinel, are able to recognize alteration in the 
microenvironment and predispose the immune system response. The relationship between cancer and virus 
infection is well documented. High-risk Human Papillomavirus (HR-HPV) has a well-characterized 
transforming property and has been associated with squamous cell carcinoma of the ano-genital and oral tracts. 
Transforming ability of HR-HPVs is based on the function of E6 and E7 viral oncoproteins, which interact and 
inactivate p53 and pRb oncosuppressors, respectively. Recently, it was demonstrated that HPV oncoproteins are 
also able to affect a number of microRNAs (miRNAs) regulating the expression of genes involved in proliferative 
control. For these reasons DC-based vaccines targeting oncogenic E6 and E7 are ideal candidates to elicit strong 
immune responses. Here we summarize significant data about the analysis of TME in HPV-induced 
tumorigenesis. We also report original results produced by cytotoxic T lymphocyte (CTL) in vitro priming 
against E6 and E7 HPV16 antigens, performed using human monocyte-derived dendritic cells. Dendritic cells, 
maturated by the exposition to necrotic or apoptotic keratinocytes expressing both oncoproteins of HPV16, show 
different expression levels of specific maturation markers. Evidence indicating the ability of necrotic 
keratinocytes to alter the microRNA profile in DCs, macrophages (MΦ) and Langerhans cells (LCs) compared 
to prototypical stimuli as bacterial lipopolysaccharide was also provided. We can speculate that, based on 
transformed cells death pathway (i.e. apoptosis versus necrosis), virus-induced immune alterations might show 
different results in creating an immunotolerogenic microenvironment during the carcinogenesis process. 
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Introduction 
The inception of tumors is a process not yet well 
understood that requires a subversion of the immune system 
[1]. It is not clear the exact order of events initiating a tumor, 
but it is critical the concomitant presence of mutations in 
oncogenes or tumor-suppressor genes in a tissue cell and 
settle of chronic inflammation [2] that directly and indirectly 
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create a mutagenic microenvironment [3]. Tumor 
microenvironment (TME) is a complex and dynamic system 
constituted by different types of cells engaged by tumor cells 
(fibroblasts, endothelial cells, smooth muscle cells, 
granulocytes, B, T and Natural Killer lymphocytes, mast 
cells, macrophages and dendritic cells) and extracellular 
matrix surrounding cancer cells [2, 4, 5]. Cancer cells secrete 
cytokines and chemokines to modulate TME and to recruit 
immune cells for regulating tumor development. These tumor 
cells-derived cytokines could, depending on the case, 
reinforce or repress the inflammatory microenvironment, 
suppress the activation of anti-tumor immune cells 
promoting at the same time angiogenesis, tumor cells 
invasion, mobility, extravasation and intravasation in 
metastatic site [2,6,7]. 
During the cancer initiation, TME is composed of 
inflammatory factors, like damage-associated molecular 
patterns (DAMPS), pathogen-associated molecular patterns 
(PAMPS) and cytokines as TNF-α, IFN-γ, IFN-α/β [8-10], that 
chronically stimulate cells of the innate and adaptive immune 
system. Once tumors have established, TME changes, 
becoming constituted by immune modulatory cytokines like 
IL-4, IL-13 and growth factors like colony stimulating 
factor-1 (CSF1) and granulocyte/macrophage colony 
stimulating factor-1 (GM-CSF) leading to an immune 
suppressive environment [2]. 
Macrophages and dendritic cells (DCs) play a central role 
among the immune cells recruited in the TME. These cells 
are characterized by high diversity and plasticity [4]. In 
addition, they recognize different external stimuli redefining 
in this way their transcription profile. Receptor engagement 
typically leads to the activation of multiple signal 
transduction pathways [11] that results in a response in DCs 
which is dependent on the peculiar transcriptional cascade 
activated. This temporal cascade leads to the expression of 
transcription factors, signaling molecules, cytokines, 
chemokines, effector proteins and regulators of metabolism, 
cell growth and cell survival that, possibly, determinate the 
immune response [12]. Recently, it was demonstrated that 
such expression is also modulated by microRNAs (miRNAs). 
MiRNAs have unique expression profiles in cells of the 
innate and adaptive immune systems and have critical roles 
in modulating cell differentiation, lineage specification, and 
effector functions [13]. Indeed, the engagement of pattern 
recognition receptors (PRRs) by their PAMPs agonists 
regulates the expressions of several miRNAs both by up- or 
down-modulating them. Many of these miRNAs target the 
expression of PPRs themselves as well as of different 
signaling intermediates and transcription factors involved in 
the activation of macrophages or in DCs activation and 
maturation [14]. Therefore, they play a pivotal role in the 
negative regulation of these functions thereby dampening 
pro-inflammatory state and/or avoiding autoimmune 
responses. DCs are fundamental to the beginning of 
tumor-specific immune responses. Understanding the TME 
role and its composition is necessary to increase the success 
of DC-based therapies [15]. Indeed, a DCs feature is to present 
to CD8+ T cells fragments of exogenously acquired antigens, 
loaded into peptide/MHC class I complexes, in a process 
called cross-presentation [16,17]. Recently, some studies have 
underlined how the capability of any subset of DCs to 
cross-present antigens in an optimal way is linked to the 
“quality” of DC activation [18,19]. Inflammatory cytokines, 
CD40 signaling (as provided by helper CD4+ T cells) and 
Toll-like receptor ligands can decide the maturation fate of 
DCs and consequently prime them for antigen 
cross-presentation [20, 21]. As stated before, DCs exhibit on 
plasma membrane distinct classes of PRRs to detect the 
“signal 0” or, rather, the recognition of the danger factors. 
These PRRs include the nucleotide oligodimerization domain 
(NOD)-like receptors (NLRs), retinoic acid-inducible gene-1 
(RIG-1)-like receptors (RLRs), absent in melanoma 2 
(AIM2)-like receptors (ALRs), the receptor for advanced 
glycation end products (RAGE) and toll-like receptors 
(TLRs) [11, 22]. 
According to a recent technique, DCs are directly isolated 
from cancer patients thereby by-passing the immune 
suppressive action of TME. The protocol based on these DCs 
was applied to specifically prime in vitro CTLs against 
different tumor-associated antigens, such as cancer-testis, 
tumor-mutated or aberrantly expressed normal genes as well 
as genes encoding viral proteins [23]. Various procedures exist 
to prime DCs in order to properly mature them, for 
stimulating an effective antigen specific CTL immune 
response, even if the obtained results are discordant [24-30]. In 
one of these methods, tumor cells are killed ex vivo and used 
to mature DCs. Cancer cells can die via different 
mechanisms, including necrosis and apoptosis. While 
necrosis is caused by injury or strong stress of the cell and is 
characterized by collapse of cell membrane integrity and a 
release of DAMPS [31], apoptosis is the process of 
programmed cell death triggered by several signals resulting 
in a high regulated process of intracellular destruction [32, 33]. 
The main characteristic of apoptotic cells is the maintenance 
of membrane integrity, at least in the first phase of the 
process, that prevents the release of danger signals [34]. 
Apoptotic and necrotic cells possibly produce different 
molecular inputs leading to divergent DC maturation and, by 
consequence, elicitation of immune responses [35]: necrotic 
cells induce immune stimulation, whereas apoptotic cells 
induce tolerance [36, 37]. By contrast, a new concept of cell 
death is arising: the cells can die in immunogenic cancer cell 
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death (ICD) or non-immunogenic cancer cell death (NICD) 
[38, 39], depending on the lethal stimulus that they have 
received [39-41]. Danger-associated molecular patterns, such as 
heat-shock proteins (HSPs), high mobility group box 1 
(HMGB1) and ATP, are important in producing ICD. They 
are released, secreted or exposed on the plasma membrane in 
response to stress or death [35]. Interestingly, pre-apoptotic 
tumor cells can expose or secrete/release them [42]. Moreover, 
at late phase of apoptosis (also called secondary necrosis), 
the cell membrane looses integrity and DAMPs are released 
thus producing high ICD. This scenario helps to better 
understand why, in several studies, DCs loaded with 
apoptotic cells were more effective than DCs loaded with 
necrotic cells at eliciting significant CTL responses in murine 
models [43-45]. Other studies suggest, on the other hand, that 
necrotic cells are better than apoptotic cells to efficiently 
stimulate the maturation of DCs by using in vitro pulsing 
protocols [46]. 
Tumor Microenvironment in HPV-induced tumorigenesis 
Most of cancers are caused by acquired somatic mutations 
and environmental factors. Among these factors, chronic 
infection has been accepted as a major driver of 
inflammation-induced tumorigenesis. Indeed, up to 26% of 
all cases of cancer worldwide are associated with microbial 
infection and it is plausible that this estimate may be rather 
low [47-49]. Human Papillomaviruses (HPVs) are small DNA 
viruses associated with the risk to develop both benign and 
malignant lesions in different anatomic sites. The life cycle 
of HPVs appears strictly correlated to the differentiation 
program of keratinocytes. The virus is able to infect the basal 
layer of the squamous epithelium and to initiate a producing 
persistent infection favoring tumor development by 
deregulating cell proliferation and inhibiting apoptosis [50]. 
High-risk Human Papillomaviruses (HR-HPVs) are the 
etiological agent of cervical cancer and are responsible for 
about 20% of all human tumors associated with infection. 
Every year, more than 500,000 new cervical cancer cases and 
275,000 deaths are recorded in the world [23]. 
HR-HPV oncoproteins E5, E6 and E7 are the primary 
viral factors responsible for initiation and progression of 
cervical cancer [51]. However, they are necessary but not 
sufficient to the tumor development. Indeed, in order to 
obtain the transformation of the epithelial host cells, the 
capability of HR-HPVs to inhibit the immune response, 
impair cellular gene expression and promote epigenetic 
mutations [52-54] appears necessary. 
The persistent infection of HPVs is a promoter of chronic 
inflammation. In particular, HPVs have the capability to 
deregulate TLR expression. TLRs mediate inflammation and 
their expression occurs in tumor, immune, and stromal cells, 
which are all known to facilitate chronic inflammation that 
primes the tumor microenvironment for more aggressive 
disease phenotypes. TLR activation mediates immune 
suppression and reduces tumor surveillance. In cancer, the 
TLRs have emerged as important participants in shaping the 
tumor microenvironment as they mediate both pro- and 
anti-tumorigenic pathways [55]. It has been reported that 
HPV16 E7 can down-regulate the expression of TLR-9, an 
innate immune receptor that recognizes unmethylated 
double-stranded DNA CpG motifs in the genome of HPV. In 
order to suppress TLR-9 expression, E7 oncoprotein induce a 
transcriptional repressive complex, composed by NF-κB 
p50-p65, ERα, and chromatin modifying enzymes [48]. 
Proinflammatory cytokines and chemokines, such as IL-1β 
and CCL5 are inhibited by HR-HPV16 and 18 to favor viral 
persistence [56]. Moreover, HPV16, 18 and 31 are able to 
impair the function of the Interferon (IFN) inducible antiviral 
genes like Interferon-induced protein with tetratricopeptide 
repeats 1 (IFIT1) and Interferon-induced GTP-binding 
protein (MX1), proapoptotic genes (i.e. TRAIL and XAF1), 
and pathogen recognition receptors like TLR3, RIG-I, and 
MDA5 [57]. In addition, in cervical cancer as well as in other 
tumors, the expression of different miRNAs is considerably 
modified. In particular, miRNAs with anti- or 
pro-tumorigenesis properties seem to be affected by 
oncogenic HPVs principally through the activity of E6 and 
E7 viral oncoproteins [58, 59]. Among the miRNAs which are 
deregulated in HPV-induced transformed cells it is important 
to highlight miR-21, miR-34a, miR-98, miR-146a, miR-155 
and miR-223 because their expression is regulated by 
TLR-signaling pathways or vice versa. 
Research Aim 
The aim of this study was to understand how dendritic 
cells are influenced in their differentiation and maturation 
during the E6 and E7 HR-HPV mediated transformation. To 
achieve this goal we evaluated the ability of DCs to 
differently recognize necrotic or apoptotic material derived 
from keratinocytes immortalized with HPV-16 E6 and E7 
oncoproteins. Moreover, the differences in DC maturation 
depending on some miRNAs expression have been 
evaluated. 
Results and Discussion 
To evaluate the rate of maturation of the dendritic cells, 
monocytes from peripheral blood were purified from buffy 
coat by using, sequentially, cell separation in Ficoll gradient 
and cell purification with immune-magnetic anti-CD14 
microbeads (see Materials and Methods). Subsequently, the 
purified monocyte population was differentiated in vitro by 
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the addition of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and interleukin 4 (IL-4) in the monocyte 
culture medium for 5 days of stimulation to achieve 
immature monocyte-derived dendritic cells (iMDDCs). 
Monocytes-derived dendritic cells are able to uptake 
extracellular K16 
The main characteristic of the iMDDCs is the ability to 
uptake extracellular material by using several types of 
mechanisms, even if this feature depends on the effectiveness 
of the differentiation stimuli [60]. 
To evaluate whether the differentiation protocol generates 
iMDDCs able to uptake material from our cell system, we 
perform a flow cytometry assay of internalization of 
CFSE–labeled apoptotic bodies from keratinocytes 
immortalized by transduction with a recombinant HPV16 
E6/E7 expressing pLXSN retrovirus (K16 cells). As shown 
in fig.1, iDCs acquire the highest percentage of fluorescence 
after 4 hours of pulsing. The internalization of K16 derived 
apoptotic bodies is an active process because it was reduced 
when the incubation was performed at 4°C rather than at 
37°C. Moreover, the percentage of CFSE-positive iDCs does 
not change significantly after ON incubation of DC with 
CFSE-labeled apoptotic bodies. This is probably due to the 
induction of the maturation process of the iDCs following to 
the apoptotic bodies uptake and processing. Taken together, 
these results show the ability of iMDDCs to uptake 
extracellular K16 cells. 
Apoptotic or necrotic K16 cells lead to a different 
maturation pattern of iDCs 
Dendritic cell maturation consists of a series of cellular 
processes that occur in the iDCs subsequent to the 
recognition of danger molecules or extracellular antigens by 
one or more receptors on the surface of their plasmatic 
membrane. This phase in the immune response is called 
“signal 0” because every mediator, cell and part of cell 
composing the microenvironment surrounding the iDCs is a 
potential main character in the effectiveness of the dendritic 
cell maturation for innate immune or adaptive immune 
response or for immune tolerance [61]. 
Once established that 48 hours of iMDDCs pulsing with 
K16 material is the best time for theirmaturation (data not 
shown), we evaluated whether necrotic fragments or 
apoptotic bodies derived from K16 cells are able to induce 
DCs maturation. The fig.2 shows expression levels of the 
maturation markers CD83 and CD86 and of the MHC-I. 
Immature DCs pulsed with K16 apoptotic bodies show a 
higher expression of MHC-I than iDCs pulsed with K16 
necrotic fragment, whereas the expression level of CD86 is 
Figure 1. Evaluation of iDCs effectiveness to uptake K16 fragments. Immature DCs were pulsed at 37°C (upper panels) or 4°C (lower 
panels) for 1, 2, 4, 12 hours with K16 apoptotic bodies derived from K16 cells incubated with CFSE (0.3 nM) at 37°C for 10 min and then induced 
to apoptotic death by hydrogen peroxide (0.9 μM). 
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highest in cells incubated with necrotic fragments. 
CD8+ T cells activation does not change on the basis of 
DC maturation stimulus 
To date there are no assays able to check 
cross-presentation of exogenous added antigens to mDC. 
This leads to analyze it only by indirect methods, such as 
quantification of interferon-γ (IFN-γ) secretion by 
mDC-stimulated CD8+ T cells or by cytotoxic T lymphocytes 
(CTLs) functional assay [16]. 
An effective CD8+ T cells activation requires a strong and 
durable interaction between the T-cell receptor and the 
MHC-I/antigenic peptide complex (signal 1), the interaction 
among co-stimulator molecules on the surface of mature DCs 
(mDCs) and CTLs (signal 2) and a productive secretion of 
inflammatory cytokines and chemokines by mDCs, CD4+ T 
cells and CTLs (signal 3). To evaluate the effectiveness of 
CTL activation against K16 cells in relation to the type of 
iDC pulsing, two in vitro priming protocols have been 
performed. In the first one, CD8+ T cells from peripheral 
blood mononuclear cells (PBMC) were stimulated by 
mMDDCs derived from iMDDC pulsed with K16 apoptotic 
bodies (apo-mDCs) whereas in the second one, CD8+ T cells 
were incubated with iMDDC pulsed with K16 necrotic 
fragments (necro-mDCs). In both cases cell cultures were 
supplemented with IL-7 (only during the first round) and 
IL-2 to support lymphocytes proliferation. At the end of each 
CTL priming protocol, a flow cytometric, non radioactive, 
CTL assay was performed using K16 as target cells. 
Fig.3 shows an increase of 2.19 times of the CFSE+/PI+ 
events in K16 co-cultured with CTLs stimulated with 
apo-mDCs with respect to control (first lane), while the 
Figure 2. Analysis of the expression levels of DC maturation markers in apo-mDCs and necro-mDCs.  Immature DCs were pulsed with 
K16 apoptotic bodies or K16 necrotic bodies for 48 hours.  Necrotic K16 cells were obtained by 3 cycles of rapid freeze/thaw. The expression 
levels of CD83, CD86 and MHC-I were assessed to evaluate the DCs maturation. 
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increase of the CFSE+/PI+ events in K16 co-cultured with 
CTLs stimulated with necro-mDCs is 2.2 times (second line). 
These results suggest that the differences on maturation 
markers expression between necro-mDC and apo-mDC were 
not linked to a difference in CD8+ T cells activation. 
miRNAs expression levels show a representative 
signature for each APC population 
The APCs are characterized by high diversity and 
plasticity [4] and TME is composed by different populations 
of APCs. It is known that there is a continuous 
communication among cells of the immune system to 
establish and/or amplify cellular tolerogenic and/or 
immunogenic functions [62]. The perception of “signal 0” 
produces different functional responses considering the 
population of APC. It is important to understand the response 
of every APC composing the TME to determine the direction 
of the immune system response. MicroRNAs also participate 
in directing APCs differentiation and maturation, probably 
because miRNAs and other epigenetics changes promote 
plasticity and achievement of a broad range of differentiation 
fate of APCs [63]. 
Table 1 resumes some of the most studied miRNAs 
associated to the regulation of DCs differentiation and 
maturation. 
Figure 3. Flowcytometric cytotoxic assay on lymphocytes T CD8+ primed by apo-mDCs or necro-mDCs. The 
apo-mDCs or necro-mDCs were co-cultured in RPMI-1640 complete medium with IL-2 (50 U/ml) and IL-7 (50 ng/ml) and 
with autologous peripheral blood lymphocyte (PBL) derived from monocytes-depleted PBMC (responder cells) for a week. 
Responder cell stimulation was repeated five times for a total of 5 weeks. 
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Table 1. MiRNAs associated to the differentiation or maturation of DCs and LCs 
DENDRITIC CELLS MATURATION DIFFERENTIATION 
miR-146a [79,80] Taganov 2006, Bai 2012  
miR -155 [13, 81-85] Lu 2011, Dunand-Sauthier 
2011, Zhou 2011, Turner 2011, 
Martinez-Nunez 2009 Ceppi 2009 
 
Let-7i [86] Busch e Zernecke 2012  
miR -21  [87,88] Cheng 2010, Hashimi 2009 
miR -24  [89] Fordham 2015  
miR -22 [90] Liang 2015  
miR -34  [87,88] Cheng 2010, Hashimi 2009 
miR -148 [91] Liu 2010  
miR -142-3p [92] Sun 2011  
miR -30b  [89] Fordham 2015  
miR -106b [93] Tang 2015   
miR -200b  [94] Liu 2015 
   
LANGERHANS CELLS MATURATION DIFFERENTIATION 
miR -146a  [95,96] Heinz 2006, Park 2015 
miR -155 [84] Martinez-Nunez 2009  
miR -223 [97] Mi 2013  
 
Analysis of miRNA expression has been performed to 
evaluate how some specific signals produce different 
responses among several populations of APCs. First of all, 
three populations of APCs were differentiated starting from 
peripheral blood monocytes: macrophages (MΦ) 
differentiated in the presence of GM-CSF; DCs differentiated 
in the presence of GM-CSF and IL-4; Langerhans cells (LCs) 
differentiated in the presence of GM-CSF, IL-4 and TGF-β. 
Each population was maturated by pulsing the cells with 
necrotic fragment of K16 or, as a positive control, with LPS 
for 48 hours. We focused our attention on miRNA-146a and 
miRNA-98 because mir-146a is central in the DCs 
differentiation and/or maturation [13,64], while mir-98 
negatively regulates IL-10 production in macrophages [65]. 
The expression levels of miR-146a and miR-98 were 
analyzed by Real-Time RT-PCR analysis. Fig.4 shows an 
induction of miR-146 expression and a reduction of miR-98 
expression in MΦ and DCs after LPS stimulation, while 
miR-146a expression is 11 times increased in LCs stimulated 
with LPS. Conversely, the trend of the expression levels of 
miR-146a and miR-98 is similar in DCs and LCs when 
pulsed with necrotic fragment of K16 cells. MΦ exhibit an 
evident reduction of miR-146a and miR-98 expression. The 
obtained data confirm how the same stimulus may produce 
different effects in different populations of APCs. 
The development of the tumors create a particular 
microenvironment leading to the promotion of cancer 
progression and metastasis hijacking, at the same time, the 
innate and adaptive immune cells activities [23]. Evidence 
indicates how the DCs are fundamental in such a regulation. 
Since several studies have shown that vaccination with DCs 
pulsed with tumor cell lysates could induce significant 
antitumor immunity [66,67], even if with variables outcomes, it 
appears fundamental to understand what is the best way to 
adequately mature DCs in order to obtain a productive T 
cells cross-priming. One of the main functions characteristic 
of DCs is the phenotypic heterogeneity that allows them to 
respond to the wide spectrum of stimuli composing the TME. 
Among these stimuli it can be found a plethora of danger 
signals and molecules linked to cell death. Until now, among 
the different types of cell death, apoptosis and necrosis are 
considered the opposite extremes: a programmed cell death 
versus an incidental cell death. Recently, this difference 
starts to be smaller, being the necrosis subjected to regulation 
[68] and apoptosis in late phase showing similitude with 
necrosis. Evidence from several studies shows how difficult 
is to establish which is the best type of cell death to produce 
mature DCs able to stimulate CTL response [43, 69-72]. 
Our data indicate how a DC pulsing with necrotic K16 
cells produces mature DCs with expression level of 
co-stimulatory ligands higher than DCs maturated with 
apoptotic K16. Conversely, apoptosis seems to be more 
efficient than necrosis to lead DC maturation toward MHC-I 
presentation. This consideration enforces the idea that many 
factors, both DC- and microenvironment-related, regulate 
DC maturation and that differences between apoptosis and 
necrosis differentially induce tumor-specific adaptive 
immune responses [35]. In particular, apoptotic cells facilitate 
the efficient uptake and persistence of the antigen, whereas 
necrotic cells are more able to secrete DAMPs thereby 
promoting DCs activation [35]. Some other variables, like the 
duration of the apoptotic stimulus and/or the method used to 
induce necrosis and apoptosis, have to be evaluated. Indeed, 
apoptotic cells may undergo secondary necrosis within the 
DC phagosomes thereby releasing DAMPs with consequent 
more immunogenic effects [35]. Another point to address is 
which type of “eat me” signals should be exposed to the 
phagocytes [41]. For example, apoptotic cells do not normally 
release HMGB1, a mediator of recruitment of monocytes and 
iDC [73], even after undergoing secondary necrosis, because it 
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is bound firmly to chromatin [74]. Different ways to induce 
apoptosis could result in a higher release of biologically 
active HMGB1 and, hence, in a higher immunogenic 
response. 
Materials and Methods 
Cell cultures 
Human Foreskin Keratinocytes were isolated as described 
by Viac et al. [75]. The keratinocytes expressing E6 and E7 
proteins of HPV-16 and HPV-38 (K16 and K38 respectively) 
were obtained by viral transduction of HFK with pLXSN as 
described by Caldeira at al. [76]. All cells were grown at 37°C 
and 5% of CO2 atmosphere in KBM-Gold media 
(Keratinocyte Basal Medium,) complemented with 
KGM-Gold Single Quote Kit (both from Lonza). 
The C33A cell line, derived from a biopsy of a cervix 
tumor [77] and negative for HPV was cultured in RPMI-1640 
media complemented with heat inactivated fetal bovine 
serum (iFBS, Lonza) 10%. 
Monocytes purification and APCs differentiation 
Monocytes purification was performed from Buffy-coat of 
healthy donor provided by the “Centro di Medicina 
Trasfusionale, Policlinico Umberto I” in Rome. Peripheral 
blood mononuclear cells were obtained by centrifugation on 
Ficoll gradient (Lympholyte-H, Cederlane) and monocytes 
were isolated by subsequent positive selection using 
anti-human CD14 magnetic micro-beads (MACS, Miltenyi 
Biotechology) according to the manufacturer’s instructions. 
Purity of the monocytes preparation was checked by flow 
cytometry using fluorescein isothiocyanate 
(FITC)-conjugated anti-CD14 antibody (clone UCHM-1, 
Becton Dickinson). To induce the differentiation of 
monocytes in different cellular subpopulations the following 
cytokines were added in culture for 5 days to RPMI-1640, 
iFBS 10%: GM-CSF 50 ng/ml (PeproTech) to induce 
differentiation into inflammatory M1 macrophages; GM-CSF 
50 ng/ml plus IL-4 25 ng/ml (PeproTech) to induce 
differentiation to immature DC; GM-CSF 50 ng/ml, IL-4 25 
ng/ml and TGF-β 15 ng/ml (PeproTech) to induce 
differentiation into immature Langerhans cells. 
Internalization assay 
K16 cells were incubated with Carboxyfluorescein 
Succinimidyl ester (CFSE, Invitrogen) 0.3 nM at 37°C for 10 
Figure 4. The miR-146a and miR-98 expression levels in macrophages (MΦ), immature dendritic cells (iDC) and immature Langerhans 
cells (iLC) stimulated by LPS or necrotic K16 cells. Macrophages, immature dendritic and Langerhans cells were stimulated for 48 hours with 
LPS (10ng/ml) or K16 necrotic fragments. Total RNA was isolated, miR-98 and miR-146a expression levels were analyzed by Real Time 
RT-PCR and compared to untreated APCs. 
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minutes in PBS then extensively washed with PBS 3% 
bovine serum albumin (BSA) to remove the excess of CFSE. 
Apoptosis of K16 was induced by incubating cells for 24 
hours in RPMI-1640, iFBS 10% with hydrogen peroxide 0.9 
μM. Immature DCs were pulsed with CFSE-labeled 
K16-derived apoptotic bodies for 1, 2, 4, 12 hours at 37°C or 
for 4, 12 hours at 4°C. Fluorescence of the immature DCs 
(iDCs) was evaluated by flow cytometry. 
Maturation of the iDCs 
DC maturation was obtained by pulsing iDCs for 48 hours 
with K16 apoptotic bodies, obtained as described in the 
previous section, (apo-mDCs), or for 48 hours with K16 
necrotic fragments, obtained by 3 cycles of rapid freeze/thaw 
of K16 cellular pellet resuspended in sterile H2O, 
(necro-mDCs). The evaluation of DC maturation was 
performed by flow cytometry analyses of the following 
surface maturation markers: CD83 (clone HB15e BD 
Biosciences – Pharmingen), CD86 (clone BU63 Cymbus 
Biotechnology) and MHC-I (clone W6/32, Cymbus 
Biotechnology). 
In vitro immunization 
The apo-mDCs or necro-mDCs were co-cultured with 
autologous peripheral blood lymphocyte (PBL) derived from 
monocytes-depleted PBMC. The co-culture APC/PBL was 
performed at 1:10 ratio in RPMI-1640 media complemented 
with iFBS 10%, IL-2 50 U/ml (Proleukin, Chiron) and IL-7 
50 ng/ml (PeproTech). IL-2 was added in culture every 3 
days and after 1 week cells were collected and stimulated 
again with another set of APCs (differentiated and maturated 
as described before) using the same conditions. Responder 
cells stimulation was repeated five times for a total of 5 
weeks. 
Flow Cytometric Cytotoxic assay 
At the end of the fifth round of restimulation, K16 and 
C33A cells, used as control, were stained with CFSE as 
already described and used as target cells. Subsequently, 
targets were co-cultured with responder cells at 37°C for 4 
hours in a 100:1 ratio responder/target. Finally, cells were 
counterstained with Propidium Iodide (PI 10 μg/ml) and 
analyzed by flow cytometry by measuring the percentage of 
CFSE+ cells able to uptake PI, being only the double positive 
events the died target cells. The rate of K16 death 
specifically due to E6/E7 recognition was determined by the 
difference between the percentage of the CFSE+PI+ of K16 
and control C33A cells. 
Flow Cytometry 
All the cytometric analyses were performed on a FACs 
ARIA II sorter (BD Biosciences). At least 10000 events were 
recorded for each sample using FACs DiVa software (v6.1.1, 
BD Biosciences). Data were analyzed using FloJo Software 
(v8.7, Three Star). 
Total RNA extraction, cDNA synthesis and Real-time RT 
PCR 
Macrophages, dendritic and Langerhans cells were 
obtained as previously described and were stimulated for 48 
hours with LPS (Sigma) 10 ng/ml or K16 necrotic fragments. 
Total RNA was isolated using the mirVanaTM miRNA 
Isolation Kit according to manufacturer’s instructions. RNAs 
were reverse transcribed in 10 μl reactions with the relevant 
specific primer pool of miR-98 and miR-146a (TaqMan 
MicroRNA Single Assay and Reverse Transcription Kit) 
according to the manufacturer’s instructions. cDNAs (4 μl of 
a 1:10 dilution in DEPC–H2O) were quantified in 20 μl 
reactions containing 10 μl Universal PCR Master Mix and 1 
μl of the individual TaqMan MicroRNA Assay using a 
7000HT Fast Real-Time RT-PCR system. Results were 
analyzed with SDS software (v2.2). All the kits, the Real 
Time apparatus and the software were from Applied 
Biosystems. The obtained CT values were converted into ΔCT 
values (endogenous control gene: RNU6) and further into 2– 
ΔΔCT [78]. Data were expressed as fold of induction using as 
comparison no-treated APCs. 
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